Buy Drugs Online:
Drugs Information:
Drugs List

1. Name Of The Medicinal Product

Minims Tropicamide 0.5 %.

2. Qualitative And Quantitative Composition

Clear, colourless, sterile eye drops containing tropicamide Ph. Eur. 0.5 % w/v.

3. Pharmaceutical Form

Single-use, sterile eye drops.

4. Clinical Particulars

4.1 Therapeutic Indications

As a topical mydriatic and cycloplegic.

4.2 Posology And Method Of Administration

Adults (including the elderly):

1 drop followed by a second drop after an interval of 5 minutes. A further 1 drop may be instilled after 30 minutes, if required.

Children:

At the discretion of the physician.

4.3 Contraindications

Do not use in patients with a known hypersensitivity to tropicamide.

Tropicamide is contraindicated in narrow angle glaucoma and in eyes where the filtration angle is narrow, as an acute attack of angle closure glaucoma may be precipitated.

4.4 Special Warnings And Precautions For Use

Use with caution in an inflamed eye, as hyperaemia greatly increases the rate of systemic absorption through the conjunctiva.

Care should be exercised in small children.

Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially advisable in children.)

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

None known.

4.6 Pregnancy And Lactation

Metalyse

10,000 units powder and solvent for solution for injection

Tenecteplase

Read all of this leaflet carefully before you start receiving this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

1. What METALYSE is and what it is used for
2. Before you receive METALYSE
3. How is METALYSE administered
4. Possible side effects
5. How to store METALYSE
6. Further information

What Metalyse Is And What It Is Used For

METALYSE is a powder and solvent for solution for injection. This means that each pack contains:

  • one vial of 10,000 units METALYSE powder and one pre-filled syringe containing 10 ml water for injections.

Before use, the solvent (water for injections) is added to the powder to form a solution that is given by injection.

METALYSE belongs to a group of medicines called thrombolytic agents. These medicines help to dissolve blood clots. Tenecteplase is a recombinant fibrin-specific plasminogen activator.

METALYSE is used to treat myocardial infarctions (heart attacks) within 6 hours after the onset of symptoms and helps to dissolve the blood clots that have formed in the blood vessels of the heart. This helps to prevent the damage caused by heart attacks and has been shown to save lives.

1. Name Of The Medicinal Product

Mirtazapine 15 mg Orodispersible Tablets

2. Qualitative And Quantitative Composition

Each orodispersible tablet contains 15 mg mirtazapine.

Excipients: aspartame (E951) 3 mg, sulphites 0.000015 mg.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Orodispersible tablet.

White to off-white, round, flat tablets with bevelled edges and plain on both sides.

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment of episodes of major depression.

4.2 Posology And Method Of Administration

Adults

The effective daily dose is usually between 15 and 45 mg; the starting dose is 15 or 30 mg.

Mirtazapine begins to exert its effect in general after 1-2 weeks of treatment. Treatment with an adequate dose should result in a positive response within 2-4 weeks. With an insufficient response, the dose can be increased up to the maximum dose. If there is no response within a further 2-4 weeks, then treatment should be stopped.

Elderly

The recommended dose is the same as that for adults. In elderly patients an increase in dosing should be done under close supervision to elicit a satisfactory and safe response.

Children and adolescents under the age of 18 years

Mirtazapine should not be used in children and adolescents under the age of 18 years as efficacy was not demonstrated in two short-term clinical trials (see section 5.1) and because of safety concerns (see sections 4.4, 4.8 and 5.1).

Renal impairment

1. Name Of The Medicinal Product

Minims Dexamethasone 0.1% w/v Eye Drops.

2. Qualitative And Quantitative Composition

Dexamethasone sodium phosphate Ph Eur 0.1% w/v.

3. Pharmaceutical Form

Single-use, sterile eye drops.

A colourless solution when examined under suitable conditions of visibility, practically clear and practically free from particles.

4. Clinical Particulars

4.1 Therapeutic Indications

Non-infected, steroid responsive, inflammatory conditions of the eye.

4.2 Posology And Method Of Administration

Adults (including the elderly):

One or two drops should be applied topically to the eye up to six times a day. Note: In severe conditions the treatment may be initiated with 1 or 2 drops every hour, the dosage should then be gradually reduced as the inflammation subsides.

Children:

At the discretion of the physician.

4.3 Contraindications

Use is contra-indicated in herpes simplex and other viral diseases of the cornea and conjunctiva, fungal disease, ocular tuberculosis, untreated purulent infections and hypersensitivity to any component of the preparation.

In children, long-term, continuous corticosteroid therapy should be avoided due to possible adrenal suppression.

4.4 Special Warnings And Precautions For Use

Care should be taken to ensure that the eye is not infected before Minims Dexamethasone is used.

These drops should be used cautiously in patients with glaucoma and should be considered carefully in patients with a family history of this disease.

This medicinal product contains phosphat

Mixtard 30 InnoLet

100 IU/ml suspension for injection in a pre-filled pen

Insulin human (rDNA)

Read all of this leaflet carefully before you start using your insulin.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, diabetes nurse or your pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, diabetes nurse or your pharmacist.

This side of the leaflet:

  • 1. What Mixtard is and what it is used for
  • 2. Before you use Mixtard
  • 3. How to use Mixtard
  • 4. What to do in an emergency
  • 5. Possible side effects
  • 6. How to store Mixtard
  • 7. Further information

Overleaf: How to use your InnoLet

What Mixtard is and what it is used for

Mixtard is human insulin to treat diabetes. Mixtard is a mixture of fast-acting insulin and long-acting insulin. This means that it will start to lower yo

Molipaxin

150mg Tablets

Trazodone Hydrochloride

Please read this leaflet carefully before you start to take this medicine. If you do not understand it or you want to know more, ask your doctor or pharmacist. Keep the leaflet, you may want to read it again.

What Is Molipaxin?

This product is called Molipaxin. Molipaxin 150mg tablets each contain 150mg of a medicine called trazodone hydrochloride. The tablets also contain lactose, calcium hydrogen phosphate, microcrystalline cellulose, maize starch, sodium starch glycollate (Type A), povidone, magnesium stearate, hypromellose, propylene glycol and colours E171 (titanium dioxide) and E172 (red iron oxide).

Molipaxin 150mg tablets are packed in blister packs containing 28 tablets.

The marketing authorisation for Molipaxin 150mg tablets is held by

Aventis Pharma Ltd.
Kings Hill
West Malling
Kent
ME19 4H
UK

They are manufactured by

Patheon UK Limited
Kingfisher Drive
Covingham
Swindon
UK

What Is Molipaxin Used For?

Molipaxin is one of a group of medicines called anti-depressants. It is used to make you feel less depressed and less anxious.

1. Name Of The Medicinal Product

MUCOGEL SUSPENSION

2. Qualitative And Quantitative Composition

Each 5ml dose contains:

Aluminium Hydroxide Gel 220mg
BP  
Magnesium Hydroxide BP 195mg

3. Pharmaceutical Form

Antacid suspension for oral administration.

4. Clinical Particulars

4.1 Therapeutic Indications

Antacid therapy in gastric and duodenal ulcer, gastritis, heartburn, gastric hyperacidity. Treatment of indigestion. Relief of symptoms of heartburn and dyspepsia associated with gastric reflux in hiatus hernia, reflux oesophagitis and similar conditions.

4.2 Posology And Method Of Administration

Adults, elderly and children over 12 years of age:

10-20ml three times daily 20 minutes to one hour after meals, and at bedtime, or as required.

Children under 12 years of age:

Not recommended.

4.3 Contraindications

Should not be used in patients who are severely debilitated or suffering from kidney failure.

4.4 Special Warnings And Precautions For Use

None stated.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Antacids inhibit the absorption of tetracyclines and vitamins and should not be taken concomitantly.

4.6 Pregnancy And Lactation

For Mucogel Suspension no clinical data on exposed pregnancies are available.

Animal studies do not

1. Name Of The Medicinal Product

MULTAQ 400 mg film-coated tablets

2. Qualitative And Quantitative Composition

Each tablet contains 400 mg of dronedarone (as hydrochloride).

Excipients:

Each tablet also contains 41.65 mg of lactose (as monohydrate).

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Film-coated tablet (tablet).

White, oblong shaped tablets, engraved with a double wave marking on one side and “4142”code on the other side.

4. Clinical Particulars

4.1 Therapeutic Indications

MULTAQ is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile (see sections 4.3 and 4.4), Multaq should only be prescribed after alternative treatment options have been considered.

MULTAQ should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.

4.2 Posology And Method Of Administration

Treatment should be initiated and monitored only under specialist supervision (see section 4.4).

Treatment with MULTAQ can be initiated in an outpatient setting.

The recommended dose is 400 mg twice daily in adults. It should be taken as

• one tablet with the morning meal and

• one tablet with the evening meal.

Grapefruit juice should not be taken together with MULTAQ (see section 4.5).

If a dose is missed, patients should take the next dose at the regular scheduled time and should not double the dose.

Treatment with Class I or III antiarrhy

1. Name Of The Medicinal Product

Mycophenolate Mofetil 250 mg Capsules

2. Qualitative And Quantitative Composition

Each capsule contains 250 mg mycophenolate mofetil.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Capsule, hard

Light blue/peach size '1' hard gelatin capsule imprinting with 'MMF' on cap and '250' on body, containing white to off white powder

4. Clinical Particulars

4.1 Therapeutic Indications

Mycophenolate mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

4.2 Posology And Method Of Administration

Treatment with mycophenolate mofetil should be initiated and maintained by appropriately qualified transplant specialists.

Use in renal transplant:

Adults:

Oral mycophenolate mofetil should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1.0 g administered twice daily (2 g daily dose).

Children and adolescents (aged 2 to 18 years):

The recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily). Mycophenolate Mofetil capsules should only be prescribed to patients with a body surface area of at least 1.25 m2. Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed mycophenolate mofetil capsules at a dose of 750 mg twice daily (1.5 g daily dose). Patients

1. Name Of The Medicinal Product

Marevan 5mg Tablets

Warfarin 5mg Tablets

2. Qualitative And Quantitative Composition

Each tablet contains 5mg warfarin sodium BP

3. Pharmaceutical Form

Tablet

Pink coloured, flat, circular, bevel-edged uncoated tablets having 'M' breakline '5' on one side and plain on other side.

4. Clinical Particulars

4.1 Therapeutic Indications

Prophylaxis of systemic embolism in patients with rheumatic heart disease and atrial fibrillation.

Prophylaxis after insertion of prosthetic heart valves.

Prophylaxis and treatment of venous thrombosis and pulmonary embolism.

Transient attacks of cerebral ischaemia.

4.2 Posology And Method Of Administration

Adults: The typical induction dose is 10mg daily for 2 days but this should be tailored to individual requirements. The daily maintenance dose is usually 3 to 9mg taken at the same time each day. The exact maintenance dose depends on the prothrombin time or other appropriate coagulation tests.

Control tests should be made at regular intervals and the maintenance dose should be adjusted according to the results obtained. Once the maintenance dose is established, it is rarely necessary to alter it.

In emergencies, anticoagulant therapy should be initiated with heparin and warfarin together. Concomitant therapy with heparin affects the results of control tests, and should be discontinued at least six hours before the first test is carried out.

Elderly: As for adults, but dosage may need to be lowered.

Children: Dosage for children has not been established.

Method of administration: Oral.

1. Name Of The Medicinal Product

Madopar CR 100 mg/25 mg Prolonged Release Hard Capsules

2. Qualitative And Quantitative Composition

Each capsule contains 100.0mg Levodopa and 25mg Benserazide (as benserazide hydrochloride)

For excipients see section 6.1

3. Pharmaceutical Form

Prolonged-release capsules, hard.

Light blue opaque body and dark green opaque cap imprinted with ROCHE in red.

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment of all stages of Parkinson's disease. Patients with fluctuations related to levodopa plasma concentrations or timing of dose, e.g. end of dose deterioration or wearing-off effects, are more likely to benefit from switching to Madopar CR.

4.2 Posology And Method Of Administration

Adults, including the elderly

Dosage and administration are very variable and must be titrated to the needs of the individual patient.

Madopar CR capsules must always be swallowed whole, preferably with a little water. They may be taken with or without food but antacid preparations should be avoided.

In patients with nocturnal immobility, positive effects have been reported after gradually increasing the last evening dose to two Madopar CR 100mg/25mg capsules on retiring.

Patients not currently treated with levodopa

In patients with mild to moderate disease, the initial recommended dose is one capsule of Madopar CR three times daily with meals. Higher doses, in general, of Madopar CR will be required than with conventional levodopa-decarboxylase inhibitor combinations as a result of the reduced bioavailability. The initial

1. Name Of The Medicinal Product

Metformin Hydrochloride 500mg/5ml Oral Solution

2. Qualitative And Quantitative Composition

Each 5ml oral solution contains 500mg Metformin Hydrochloride.

1ml of oral solution contains 100mg Metformin Hydrochloride.

Excipients: Sodium methyl parahydroxybenzoate (E219), sodium propyl parahydroxybenzoate (E217) and maltitol liquid (E965).

Sodium = 5.3mg/5ml

Potassium = 14.5mg/5ml

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Oral Solution

Clear brown liquid.

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.

• In adults, Metformin Hydrochloride Oral Solution may be used as monotherapy or in combination with other oral anti-diabetic agents or with insulin.

• In children from 10 years of age and adolescents, Metformin Hydrochloride Oral Solution may be used as monotherapy or in combination with insulin.

A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet failure (see 5.1. Pharmacodynamic properties).

4.2 Posology And Method Of Administration

Adults:

Monotherapy and combination with other oral antidiabetic agents:

• The usual starting dose is one 5ml spoonful (500mg) 2 or 3 times daily given during or after meals.

• After 10 to 15 days the dose should be adjusted on the basis of blood glucose

Magnesium sulphate injection 50% w/v

This leaflet is to help you get the most from your medicine.

Please read this leaflet carefully BEFORE you take your medicine. If you have any questions or you want to know more about this medicine, please ask the staff looking after you.

What is your medicine?

Your medicine is called Magnesium Sulphate Injection 50% w/v. It is a sterile solution for injection and contains 1g of magnesium sulphate (the active ingredient) in each 2ml of injection. It also contains sodium hydroxide, sulphuric acid and water for injections.

Magnesium Sulphate Injection 50% w/v is supplied in cartons of 1, 5 or 10 glass ampoules each containing 2ml of solution.

Magnesium Sulphate belongs to a group of medicines called mineral supplements.

Who makes it?

The Marketing Authorisation Holder is

UCB Pharma Ltd
208 Bath Road
Slough
Berkshire
SL1 3WE
UK

It is made by

Ashton Pharmaceuticals Ltd
Vale of Bardsley
Ashton-under-Lyne
OL7 9RR
UK

What is this medicine used for?

Magnesium Sulphate Injection 50% w/v is used to treat magnesium deficiency (lack of magnesium), where

1. Name Of The Medicinal Product

Meropenem 500 mg, powder for solution for injection

2. Qualitative And Quantitative Composition

Each vial contains meropenem trihydrate equivalent to 500 mg anhydrous meropenem.

The sodium content of each vial is 2.0 mmol (45 mg).

After reconstitution with 10 ml diluent the concentration of meropenem amounts to 50 mg/ml.

For full list of excipients, see section 6.1.

3. Pharmaceutical Form

Powder for solution for injection or infusion.

White to pale yellow crystalline powder.

4. Clinical Particulars

4.1 Therapeutic Indications

Meropenem is indicated for the treatment of the following infections in adults and children over 3 months of age (see sections 4.4 and 5.1):

• Pneumonia, including community acquired pneumonia and nosocomial pneumonia.

• Broncho-pulmonary infections in cystic fibrosis

• Complicated urinary tract infections

• Complicated intra-abdominal infections

• Intra- and post-partum infections

• Complicated skin and soft tissue infections

• Acute bacterial meningitis

Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology And Method Of Administration

The tables below provide general recommendations for dosing.

The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.

1. Name Of The Medicinal Product

Minims Pilocarpine Nitrate 2%

2. Qualitative And Quantitative Composition

Clear, colourless, sterile eye drops containing Pilocarpine Nitrate 2.0% w/v.

3. Pharmaceutical Form

Sterile, single-use eye drops.

4. Clinical Particulars

4.1 Therapeutic Indications

Pilocarpine is used as a miotic, for reversing the action of weaker mydriatics and in the emergency treatment of glaucoma.

4.2 Posology And Method Of Administration

Adults (including the elderly) and children:

Instil dropwise into the eye according to the recommended dosage.

To induce miosis, one or two drops should be used.

In cases of emergency treatment of acute narrow-angle glaucoma, one drop should be used every five minutes until miosis is achieved.

4.3 Contraindications

Conditions where pupillary constriction is undesirable e.g. acute iritis, anterior uveitis and some forms of secondary glaucoma.

Hypersensitivity to any component of the preparation.

Patients with soft contact lenses should not use this preparation.

4.4 Special Warnings And Precautions For Use

Systemic reactions rarely occur when treating chronic simple glaucoma at normal doses. However, in the treatment of acute closed-angle glaucoma the possibility of systemic reactions must be considered because of the higher doses given. Caution is particularly advised in patients with acute heart failure, bronchial asthma, peptic ulceration, hypertension, urinary tract obstruction, Parkinson's disease and corneal abrasions.

Retinal detachments have been caused in susceptible individuals and those with pre-existing retinal d

1. Name Of The Medicinal Product

Maxolon® Injection

2. Qualitative And Quantitative Composition

Each 2ml ampoule contains Metoclopramide Hydrochloride BP equivalent to 10mg of the anhydrous substance.

3. Pharmaceutical Form

Clear colourless solution for intramuscular or intravenous administration.

4. Clinical Particulars

4.1 Therapeutic Indications

Adults (20 years and over)

Digestive disorders:

'Maxolon' restores normal co-ordination and tone to the upper digestive tract.

'Maxolon' relieves the symptoms of gastro-duodenal dysfunction including:

Dyspepsia, Heartburn,
Flatulence, Sickness,
Regurgitation of bile, Pain

These symptoms may be associated with such conditions as:

Peptic ulcer, Duodenitis,
Reflux oesophagitis, Hiatus hernia,
Gastritis, Cholelithiasis and

1. Name Of The Medicinal Product

Miochol®-E, 20mg, Powder and Solvent for Solution for Intraocular Irrigation.

2. Qualitative And Quantitative Composition

Each powder vial contains 20mg acetylcholine chloride.

Miochol-E contains 10mg/ml of acetylcholine chloride, (20mg in 2ml) upon reconstitution.

For excipients, see section 6.1.

3. Pharmaceutical Form

Powder and Solvent for Solution for Intraocular Irrigation.

Vial: white solid or powder

Ampoule: clear, colourless solution

Filter: syringe filter

4. Clinical Particulars

4.1 Therapeutic Indications

To obtain rapid and complete miosis after delivery of the lens in cataract surgery as well as in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid complete miosis is required.

4.2 Posology And Method Of Administration

Miochol-E is for intraocular irrigation only. A freshly prepared 1% solution should be used in the anterior chamber of the eye during surgery.

Adults and Elderly

In most cases a satisfactory miosis, which will last for approximately 20 minutes, is produced in seconds by 0.5 - 2.0ml. A second application may be made at the discretion of the surgeon if prolonged miosis is required.

Children

Safety and effectiveness in children has not been established.

Route of administration: Intraocular irrigation during surgery.

4.3 Contraindications

There are no known contra-indications to the use of Miochol-E in cataract or anterior segment surgery.

4.4 Special Warnings And Precautions F

1. Name Of The Medicinal Product

Mycophenolate Mofetil 500mg Film-Coated Tablets

2. Qualitative And Quantitative Composition

Each tablet contains 500mg mycophenolate mofetil.

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Purple coloured, film-coated tablets, debossed with 'W417' on one side and plain on the other.

4. Clinical Particulars

4.1 Therapeutic Indications

Mycophenolate mofetil 500mg film-coated tablets are indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

4.2 Posology And Method Of Administration

Treatment with mycophenolate mofetil 500mg film-coated tablets should be initiated and maintained by appropriately qualified transplant specialists.

Use in renal transplant:

Adults: mycophenolate mofetil 500mg film-coated tablets should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1.0 g administered twice daily (2 g daily dose).

Children and adolescents (aged 2 to 18 years): the recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily). Mycophenolate mofetil 500mg film-coated tablets should only be prescribed to patients with a body surface area greater than 1.5 m2, at a dose of 1 g twice daily (2 g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose

1. Name Of The Medicinal Product

MEPRADEC 10 mg GASTRO-RESISTANT CAPSULES

2. Qualitative And Quantitative Composition

Omeprazole........................10 mg

For excipients, see section 6.1.

3. Pharmaceutical Form

Capsule, hard.

Omeprazole 10 mg Gastro-Resistant Capsule is a hard gelatin capsule with an opaque beige body, marked "10" and an opaque beige cap, marked "DP".

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment of duodenal and benign gastric ulcers including those complicating NSAID therapy. Treatment and prophylaxis of NSAID-associated benign gastric ulcers, duodenal ulcers and gastroduodenal erosions in patients with a previous history of gastroduodenal lesions who require continued NSAID treatment.

Relief of associated dyspeptic symptoms.

Treatment of oesophageal reflux disease. In reflux oesophagitis the majority of patients are healed after 4 weeks. Symptomatic relief is rapid. Relief of reflux-like symptoms (e.g., heartburn) and/or ulcer-like symptoms (e.g., epigastric pain) associated with acid-related dyspepsia.

Relief of associated dyspeptic symptoms.

Zollinger-Ellison syndrome.

Prophylaxis of acid aspiration.

4.2 Posology And Method Of Administration

The capsules should be swallowed whole with plenty of liquid (e.g., water or fruit juice) prior to a meal. It is important that the capsules should not be crushed or chewed.

Duodenal & Benign Gastric Ulcers: The usual dose is 20 mg once daily. The majority of patients with duodenal ulcer are healed after 4 weeks. The majority of patients with benign gastric ulcer are healed after 8 week

Mobic 15 mg Tablets

(Meloxicam)

Please read this leaflet carefully. It contains a summary of the information available on your medicine. The information in the leaflet applies to MOBIC 15 mg Tablets only. If after reading this you have any questions, ask your doctor or pharmacist.

What is your medicine called?

The name of your medicine is MOBIC 15 mg Tablets.

What does your medicine contain?

Each tablet contains 15 mg meloxicam as the active ingredient. The tablets also contain the following inactive ingredients: sodium citrate, lactose monohydrate, microcrystalline cellulose, povidone, anhydrous colloidal silica, crospovidone and magnesium stearate.

MOBIC 15 mg Tablets are available in cartons containing 30 tablets.

What are MOBIC 15 mg Tablets?

MOBIC 15 mg Tablets contain the active ingredient meloxicam. Meloxicam belongs to a group of medicines called non-steroidal anti-inflammatory drugs which are used to reduce inflammation and pain in joints and muscles.

The Marketing Authorisations for MOBIC 15 mg Tablets in the U.K. and Republic of Ireland are held by:

Boehringer Ingelheim International GmbH
D-55216 Ingelheim am Rhein
Germany

and the tablets are manufactured by:

Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein